Leqembi

Lecanemab, the active ingredient in Leqembi, is a monoclonal antibody presented as a 10 mg/mL solution for infusion for intravenous use. It is an anti‑amyloid disease‑modifying therapy indicated for early symptomatic Alzheimer’s disease and mild cognitive impairment due to Alzheimer’s disease in the EU.

GNH USA supplies Leqembi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing regulated access to this EU‑approved biologic. The company adheres to stringent quality standards and offers cold‑chain logistics for biologic products.

Leqembi (lecanemab) is an anti‑amyloid monoclonal antibody used in the treatment of Alzheimer’s disease. Early symptomatic Alzheimer’s disease: improves clinical outcomes by reducing amyloid plaque burden. Mild cognitive impairment due to Alzheimer’s disease: may delay progression to dementia. Alzheimer’s disease (early stage): offers disease‑modifying therapy targeting amyloid pathology.

Leqembi may cause a range of adverse reactions, most of which are often mild and transient, while some can be serious and require monitoring.

Common Side Effects: - Infusion‑related reactions: flushing, chills, shortness of breath, or rash occurring during or shortly after the IV infusion. - Headache: mild to moderate headache that may appear within hours after treatment. - Nausea: occasional nausea or upset stomach that may occur during the infusion period.

Serious or Rare Side Effects: - Amyloid‑related imaging abnormalities (ARIA): includes cerebral edema (ARIA‑E) or microhemorrhage (ARIA‑H) visible on MRI, potentially symptomatic. - Severe hypersensitivity reactions: anaphylaxis, angioedema, or severe skin rash requiring immediate medical attention. - Cerebral hemorrhage: rare intracerebral bleeding events that can be life‑threatening.

Leqembi requires careful monitoring and patient education to minimize risks. - Monitor MRI for ARIA: baseline and periodic MRI scans are recommended. - Assess renal function: adjust monitoring in patients with severe renal impairment. - Avoid use in patients with known hypersensitivity to lecanemab or excipients. - Educate patients about symptoms of ARIA: headache, confusion, visual changes. - Concomitant anticoagulants: use caution due to bleeding risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Leqembi has a limited interaction profile, but certain co‑medications require attention.

Major Interactions (Avoid): - Concurrent use with other amyloid‑targeting antibodies: increased risk of ARIA. - Anticoagulants: heightened bleeding risk with ARIA‑H. - Known hypersensitivity to lecanemab excipients: contraindicated.

Moderate Interactions (Monitor Closely): - Antihypertensives: monitor blood pressure as infusion may cause transient changes. - Non‑live vaccines: schedule at least 4 weeks apart from infusion. - Other immunosuppressants: may affect immune response and infection risk.